Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Craniofac Surg ; 2024 May 29.
Article in English | MEDLINE | ID: mdl-38810245

ABSTRACT

Horse riding is a popular yet dangerous sport, often resulting in facial traumas due to unpredictable horse reactions or falls. This retrospective study examines 20 patients. The aim of the study is to analyze maxillofacial traumas of equine origin and discuss prevention strategies. Conducted from 2004 to 2021 at our university hospital's emergency department in France, inclusion criteria encompassed patients with maxillofacial trauma admitted to the emergency department and referred to ENT and/or dentistry post-horse-related accidents. Patients were identified from the Health Data warehouse. While 35 medical files were accessed, 15 did not meet inclusion criteria. Analysis of patient parameters, including age, sex, injury date, circumstances, injury type, management, helmet usage, operative interventions, and potential sequelae, revealed a predominantly female population (16 versus 4) under 48 years old. Traumas were most prevalent in summer (80%) and frequently involved riders on foot (60%). Seventy percent of patients sustained at least 1 facial fracture, with helmet use documented in only 1 case. In conclusion, horse riding can lead to various traumas, often necessitating surgical intervention. Preventive measures such as protective helmets, even for nonmounted riders, are crucial as the literature highlights many injuries occurring due to helmet omission.

3.
Presse Med ; 47(1): 19-33, 2018 Jan.
Article in French | MEDLINE | ID: mdl-29275972

ABSTRACT

Antiresorptives and antiangiogenics are treatments that have proven effective in oncology and the treatment of osteoporosis and they are increasingly prescribed. The care of these patients requires collaboration between the prescriber and the oral health professional to establish an optimized treatment plan. Therapeutic education of the patient is essential for him to understand the issues of good oral health and the adverse effects that can be caused by these treatments. The management is essentially based on the individual benefit/risk balance resulting from the general, local and inherent of the molecule risk factors. Management of drug-related osteonecrosis of the jaw should be as early as possible.


Subject(s)
Angiogenesis Inhibitors/adverse effects , Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Jaw Diseases/chemically induced , Osteonecrosis/chemically induced , Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology , Bisphosphonate-Associated Osteonecrosis of the Jaw/pathology , Bisphosphonate-Associated Osteonecrosis of the Jaw/prevention & control , Bisphosphonate-Associated Osteonecrosis of the Jaw/surgery , Bone Density Conservation Agents/therapeutic use , Bone Resorption/drug therapy , Dental Care/methods , Diphosphonates/history , Diphosphonates/therapeutic use , History, 19th Century , History, 20th Century , Humans , Jaw Diseases/diagnostic imaging , Jaw Diseases/history , Jaw Diseases/prevention & control , Neoplasms/drug therapy , Occupational Diseases/history , Oral Surgical Procedures/adverse effects , Oral Surgical Procedures/methods , Osteonecrosis/diagnostic imaging , Osteonecrosis/prevention & control , Osteoporosis/drug therapy , Phosphorus/toxicity , Postoperative Complications/chemically induced , Tooth Extraction/adverse effects
4.
Medicine (Baltimore) ; 96(2): e5075, 2017 Jan.
Article in English | MEDLINE | ID: mdl-28079787

ABSTRACT

BACKGROUND: The purpose of pharmacovigilance (drug safety) is collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. It is meant to identify, characterize, prevent, or minimize actual or potential risks relating to medicinal products. To prevent these adverse effects and improve our practice, health professionals have a duty to report side effects to assess this risk and evaluate the benefit/risk requirements. Mitotane (Lysodren) is used for treating adrenocortical carcinoma. Currently, no side effects concerning oral and genital mucosa have been reported. CASE SUMMARY: This case report is about a 50 years old woman. Six months after the initiation on mitotane treatment, she developed erosive lesions located on the oral and vaginal mucosa. These drug reactions were diagnosed as erosive lichen planus by the biopsy. This lichenoid lesions were resistant to the usual treatments, mitotane being at the time not replaceable. CONCLUSION: This case describes an unreported adverse effect of mitotane, it is - to our knowledge - the 1st description of erosive lichenoid drug reaction due to Mitotane.


Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Lichenoid Eruptions/chemically induced , Mitotane/adverse effects , Mouth Diseases/chemically induced , Vulvar Diseases/chemically induced , Adrenal Cortex Neoplasms/drug therapy , Carcinoma/drug therapy , Female , Humans , Middle Aged
5.
Am J Clin Dermatol ; 17(2): 171-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26691521

ABSTRACT

BACKGROUND: The pathophysiology of primary burning mouth syndrome (BMS) is extensively debated but poorly understood. OBJECTIVE: The aim of the study was to evaluate neuropathic and psychological components of BMS in patients with primary BMS. METHODS: Subjects were recruited through a consultation dedicated to mouth diseases, during which a diagnosis of primary BMS was assessed. Patients answered the abbreviated Douleur Neuropathique 4 questionnaire (DN4i), the Hospital Anxiety and Depression Scale (HADS) and the questionnaire de la douleur de Saint-Antoine (QDSA), the French version of the McGill pain questionnaire. RESULTS: Thirty-five patients with primary BMS were included in the study: 31 % of them had a DN4i score in favour of neuropathic pain and 34.3 % had a HADS overall score in favour of anxiety and depressive disorder. CONCLUSION: Both physiological and psychological aspects of BMS need to be actively investigated by clinicians to successfully manage these patients. The physiological and psychological aspects are not mutually exclusive. The DN4i and the HADS are easy-to-use tools and could be used in an initial assessment of BMS patients.


Subject(s)
Anxiety/physiopathology , Burning Mouth Syndrome/physiopathology , Burning Mouth Syndrome/psychology , Depression/physiopathology , Neuralgia/physiopathology , Aged , Anxiety/epidemiology , Depression/epidemiology , Female , Humans , Male , Middle Aged , Neuralgia/epidemiology , Pain Measurement/methods , Surveys and Questionnaires
6.
Dermatology ; 228(2): 172-6, 2014.
Article in English | MEDLINE | ID: mdl-24557331

ABSTRACT

BACKGROUND: Patients with burning mouth syndrome (BMS) are frequently treated with antidepressants. Selective serotonin reuptake inhibitors (SSRIs) are increasingly used. Nonetheless, few studies have examined the effects of SSRIs in BMS. OBJECTIVE: We performed a retrospective study to confirm the need for a prospective study on this topic in the future. PATIENTS AND METHODS: 51 patients suffering from primary BMS were included in this study. RESULTS: The frequency of side effects due to SSRIs was low, with mainly digestive side effects. Treatment with SSRIs was more efficient in patients reporting a psychogenic origin for their symptoms. Antidepressants were more frequently stopped when patients did not declare such an origin. CONCLUSIONS: SSRIs appear to be effective and well tolerated. Declaring a psychogenic component may be considered as a potentiating or predictive factor for the efficacy of treatment with SSRIs. These results should be confirmed by a prospective randomised study.


Subject(s)
Antidepressive Agents, Tricyclic/therapeutic use , Burning Mouth Syndrome/drug therapy , Selective Serotonin Reuptake Inhibitors/therapeutic use , Aged , Burning Mouth Syndrome/diagnosis , Female , Humans , Male , Middle Aged , Reproducibility of Results , Retrospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...